

## PROXY


1. Approval of the sale of pharmaceutical products owned by the Company, respectively the assets related to these pharmaceutical products (brands, domains, pharmaceutical dossiers, marketing authorizations), as well as the conclusion by the Company of license agreements related to some of the transferred/owned pharmaceutical dossiers as per the informative materials made available to the shareholders




2. Empowering the Company General Manager to carry out all actions in order to implement the decision under item 1, including to identify the products (assets) which will be subject of each transactions and also the signing on behalf of the company of all the documents necessary for this purpose, observing the coordinates specified in point 1.



**3.** Establishment of the date of July **31**, 2018 as the date of identification of the shareholders being affected by the resolution;



## 4. Establishment of the date of July 30, 2018 as ex date



This proxy form has been made available in 3 (three) counterparts, having the following purposes: one for the shareholder, the second for the representative and the third to be filed in original to the issuer.

The proxy form dedicated to the Company will be accompanied by a copy of the identity document or registartion certificate of the represented shareholder.

Date \_\_\_\_ / \_\_\_\_ / 2018

\_\_\_\_\_ (name and signature of the legal representative(s)/ stamp

of the holder of securities)